Intravenous administration of human cardiac progenitor cell-derived exosomes prevented doxorubicin/trastuzumab-induced myocardial fibrosis, inflammation, and left ventricular dysfunction in rats.
Does intravenous administration of cardiac progenitor cell-derived exosomes prevent doxorubicin/trastuzumab-induced cardiac toxicity in a rat model?
Systemic administration of human cardiac progenitor cell-derived exosomes protects against doxorubicin and trastuzumab-induced cardiotoxicity in a preclinical model, highlighting a potential novel therapeutic strategy.
AIMS: Combined administration of anthracyclines (e.g. doxorubicin; Dox) and trastuzumab (Trz), a humanized anti-human epidermal growth factor receptor 2 (HER2; ErbB2), is an effective treatment for HER2-positive breast cancer. However, both agents are associated with cardiac toxicity. Human cardiac-resident mesenchymal progenitor cells (CPCs) secrete extracellular vesicles including nanosized exosomes which protect against myocardial ischaemia. Here, we investigated the effects of these exosomes using a novel model of Dox/Trz-mediated cardiotoxicity. METHODS AND RESULTS: CPCs were derived from cardiac atrial appendage specimens from patients who underwent heart surgery for heart valve disease and/or ischaemic heart disease, and exosomes were purified from CPC conditioned media. Proteomics analyses revealed that CPC exosomes contained multiple proteins involved in redox processes. Dox/Trz induced a significant increase in reactive oxygen species (ROS) in rat cardiomyocytes, which was prevented by CPC exosomes. In vivo, rats received six doses of Dox (Days 1-11), followed by six doses of Trz (Days 19-28). Three doses of either exosomes or exosome suspension vehicle were injected intravenously on Days 5, 11, and 19 in the treatment and control groups, respectively. Dox/Trz induced myocardial fibrosis, CD68+ inflammatory cell infiltrates, inducible nitric oxide synthase expression, and left ventricular dysfunction. CPC exosomes prevented these effects. These vesicles were highly enriched in miR-146a-5p compared with human dermal fibroblast exosomes. Dox upregulated Traf6 and Mpo, two known miR-146a-5p target genes (which encode signalling mediators of inflammatory and cell death axes) in myocytes. CPC exosomes suppressed miR-146a-5p target genes Traf6, Smad4, Irak1, Nox4, and Mpo in Dox-treated cells. Specific silencing of miR-146a-5p abrogated exosome-mediated suppression of those genes leading to an increase in Dox-induced cell death. CONCLUSIONS: Human CPC exosomes attenuate Dox-/Trz-induced oxidative stress in cardiomyocytes. Systemic administration of these vesicles prevents Dox/Trz cardiotoxicity in vivo. miR-146a-5p mediates some of the benefits of exosomes in this setting.
Milano et al. (2019) studied Doxorubicin/trastuzumab-induced cardiac toxicity. Intravenous administration of cardiac progenitor cell-derived exosomes vs. Exosome suspension vehicle was evaluated on Myocardial fibrosis, inflammatory cell infiltrates, inducible nitric oxide synthase expression, and left ventricular dysfunction. Intravenous administration of human cardiac progenitor cell-derived exosomes prevented doxorubicin/trastuzumab-induced myocardial fibrosis, inflammation, and left ventricular dysfunction in rats.